The ovary is a relatively frequent site of metastases from malignant neoplasms arising anywhere in the body. Ovarian metastases constitute 76% of genital tract metastases from extragenital primary tumours, of which 78% arise in the gastrointestinal tract (Mazur et al., 1984) . Secondary tumours of the ovary constitute 10% of all ovarian neoplasms (Blaustein, 1982) . In premenopausal women with colorectal cancer the incidence of ovarian metastases either found at the time of initial surgery or developing subsequently is reported to be between 13.2% and 25% (Recalde et al., 1974; Walton et al., 1976; MacKeigan and Ferguson, 1979). Similar rates have been reported for stomach cancer (Warren and Macomber, 1935; Webb et al., 1975) . The term 'Krukenberg tumour' has become dinically synonymous with the pnce of any metastasis to the ovaries, although purists contend that true Krukenberg tumours should meet the criteria established by Novak and Gray in 1938 and currently used by the WHO (Serov and Scully, 1973):
The ovary is a relatively frequent site of metastases from malignant neoplasms arising anywhere in the body. Ovarian metastases constitute 76% of genital tract metastases from extragenital primary tumours, of which 78% arise in the gastrointestinal tract (Mazur et al., 1984) . Secondary tumours of the ovary constitute 10% of all ovarian neoplasms (Blaustein, 1982) . In premenopausal women with colorectal cancer the incidence of ovarian metastases either found at the time of initial surgery or developing subsequently is reported to be between 13.2% and 25% (Recalde et al., 1974; Walton et al., 1976; MacKeigan and Ferguson, 1979) . Similar rates have been reported for stomach cancer (Warren and Macomber, 1935; Webb et al., 1975) . The term 'Krukenberg tumour' has become dinically synonymous with the pnce of any metastasis to the ovaries, although purists contend that true Krukenberg tumours should meet the criteria established by Novak and Gray in 1938 and currently used by the WHO (Serov and Scully, 1973) :
(1) presence of cancer in the ovary; (2) intracellular mucin production by neoplastic signet-ring cells; and (3) diffuse sarcomatoid proliferation of the ovarian stroma When lesions of this particular histology are analysed in terms of the primary neoplasn, gastric carcinoma is the most common source of ovarian metastases (Hale, 1968; Woodruff and Novak, 1960) . Other ovarian metastases are of nonKrukenberg type and at times may be difficult to distinguish from primary ovanan carcnoma. The frequent use of computeised tomographic (CT) nning nowadays to assess and follow up patients with tumours of the gastrointestinal tract results in the discovery of otherwise unsuspected ovarian metastases, the features of which are described in a separate report (in preparation This report reviews ovarian metastases from primary gastrointestinal mlimanci regardless of whether they were classal Krukenberg tumours or non-Krukenberg tumours, as in many instances it was not possible to differentiate between the two. The pathologial features of cl Krukenberg tumours are well described elsewhere (Wong et al., 1986) . assical Krukenberg tumours are reported to occur in younger premenopausal women, occasionally occurring during or shortly after pregnancy (Ward, 1966; Holz and Hart, 1982) , suggesting a hormonal effect as one of the aetiological factors in its occurrence.
It has been postulated that the rearrangement of the ovarian surface in the post-ovulatory period and increased vascularity favour the seeding and growth of metastases (Sternberg, 1963) . The diagnosis of Krukenberg tumours has been reported to be associated with a poor prognosis (Mason and Kovalich, 1981) , but the use of aggressive chemotherapy or surgery in these patients is not well described. Endocrinological symptoms related to ovarian dysfunction have been reported (Raquiz, 1991; Scully and Richardson, 1961 (Table II) . Tlwhree patients with metachronous ovarian metastases had received adjuvant chemotherapy for resected gastric carcinoma and the ovary was the sole site of relapse. All The response to treatment was evaluated and stratified according to primary tumour type. Of the 51 patients sse in the study, 36 had measurable disease in the ovaries as well as at extrovarian sites. The overall response was partial response in eight patients (22%) and complete response in no patients. However, a total of 11 patients had a partial response at extraovarian sites, and only five of these had a partial response in the ovaries. One patient had a differential response characterised by response at an extraovarian site while the ovarian disease emained stable, and six patients responded at extraovarian sites but synchronously developed new lesions in the ovaries while stfill responding (Table HI) . The duration of response for responders was 2.5 months. The median survival for the 51 patients was 9 months, and for the patients who responded to chemotherapy was 20 months. Interestingly, three women less than 50 years who received adjuvant chemotherapy for gastric carcinoma relapsed solely in the ovary, and after surgical resection all remain alive and well 6, 10 and 28 months after surgery. Two women developed ovarian metastases while on adjuvant chemotherapy for colorectal carcinoma: one had an oophorectomy but has developed recurrent pelvc disease and the other has isolated ovarian metaa awaiting surgery.
Response to radiotherapy
Only three patients had pelvic radiotherapy, two preceding chemotherapy and one after unsuccessful chemotherapy; all patients responded, two partially and one completely.
Response to surgery
The 17 patients who had surgery had a subsequent diseasefree period oN-28 + months following surgery (Table H) .
Surgery was performed at widely differing times in the course of the patient's disease. Another explanation for the differential responses seen in at least some cases may be the true occurrence of a second primary in the ovary. In these cases the ovarian tumour would be unlikely to respond to 5-fluorouracil-based chemotherapy. However, as there was no reported family history of multiple primary cancer syndromes or other cancers, this explanation would be likely to account for only a small number of the total cases. In addition, multiple primaries are more frequent in patients less than 40 years, and only 9 of the 51 patients were in this group. It was neither ethical nor practical to biopsy all the ovarian masses. Radiologically they were presumed in the context of a proven primary lesion to be metastases. Supporting this presumption was the absence of a significant amount of ascites, seen only in four patients towards the end of treatment. Primary ovarian cancer is frequently assocated with a larg amount of ascites.
In only 30% were large ovarian masses seen on the first CT scan; the rzmainder developed while patients were on treatment and were observed over a 6 month to 2 year period.
The differential response was especially evident when the primary site was colorectal and suggests that ovarian metastases from primary colorectal cancer are relatively resistant to chemotherapy compared with non-ovarian metastases. Therefore, the ovary may be a sanctuary site analogous to the testis in other malignancies. Also suggestive of such sanctuary sites is the three cases of solitary ovarian relapw in patients who received adjuvant therapy, although no definite conclusions can be drawn. In particular, patients with primary colorectal cancer had a 40% response rate at extraovarian sites compared with a 5% (CI 0.001-0.25) response rate in the ovary, although the confidence intervals overlap because of the small number of patients (Table IV) . Patients with metastatic gastrointestinal tumours cannot be cured, but there is now evidence that patients with hepatic metastases from colorectal carcinoma have an improved survival with palliation of symptoms if they receive chemotherapy (Poon et al., 1989; Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 1993) . If palliation of symptoms at extrovarian sites can be achieved by chemotherapy, then large ovarian metastases from a colorectal primary may remain a significant source of morbidity, as this series suggests that they respond minimally to chemotherapy. Pathological studies have demonstrated involvement of the ovary in 3-8% of colorectal cancer patients (Abrams et al., 1950; Wheelock and Putong, 1959) . Prospective studies in which prophylactic oophorectomy has been performed in patients with colorectal cancer show the incidence of ovarian involvement to be between 7.4% and 11.3% (MacKeigan and Ferguson, 1979; Holtz and Hart, 1982) . Microscopic disease has been reported in 3% of patients (MacKeigan and Ferguson, 1979) . Several authors have advocated prophylactic oophorectomy for women with colorectal cancer (Burt, 1951; Barr et al., 1962; Antonaides et al., 1977; MacKeigan and Ferguson, 1979; Graffner et al., 1983 ) but this has not become accepted standard practice. The argument against prophylactic oophorectomy is the lack of evidence showing a survival benefit in any of the studies performed. A retrospective study from the Mayo Clinic (Ballantyne et al., 1985) reviewed 571 women who underwent curative resection of colon cancer. The overall 5 year survival was 78% for For patients who develop ovarian metastases subsequent to their primary surgery, a second operation is not often contemplated because of the presence of concurrent disease at other sites or because of unfitness for surgery. The small number of patients in this report who had surgery had several months disease free, which must be considered worthwhile palliation, even though they subsequently died of disease at other sites. Patients with widespread metastases who achieve a good response to chemotherapy at extraovarian sites but have unresponsive ovarian metastases causing symptoms or with impending symptoms should be considered potential candidates for palliative surgical resection or palliative radiotherapy as the few patients treated with radiotherapy all responded.
